Page last updated: 2024-12-06

pirazolac

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Pirazolac is a non-steroidal anti-inflammatory drug (NSAID) that has been investigated for its potential therapeutic effects. Its synthesis involves a multi-step process that utilizes organic chemistry principles. Pirazolac exhibits anti-inflammatory, analgesic, and antipyretic properties, similar to other NSAIDs. Research on pirazolac focuses on its effectiveness in treating inflammatory conditions, such as rheumatoid arthritis and osteoarthritis. Its mechanism of action is thought to involve the inhibition of cyclooxygenase enzymes, which are responsible for the production of prostaglandins, key mediators of inflammation. However, pirazolac also has potential side effects, including gastrointestinal disturbances and cardiovascular risks, similar to other NSAIDs. Further studies are needed to evaluate its safety and efficacy in clinical settings.'

Cross-References

ID SourceID
PubMed CID51222
CHEMBL ID249446
SCHEMBL ID153631
MeSH IDM0134270

Synonyms (33)

Synonym
pirazolac
zk-76604
pirazolac (usan/inn)
71002-09-0
D05493
zk 76 604
CHEMBL249446
zk-76 604
zk 76604
2-[4-(4-chlorophenyl)-1-(4-fluorophenyl)pyrazol-3-yl]acetic acid
pirazolaco [inn-spanish]
unii-fwy2578lp5
1h-pyrazole-3-acetic acid, 4-(4-chlorophenyl)-1-(4-fluorophenyl)-
fwy2578lp5 ,
pirazolacum
pirazolaco
einecs 275-102-3
4-(p-chlorophenyl)-1-(p-fluorophenyl)pyrazole-3-acetic acid
pirazolacum [inn-latin]
pirazolac [usan:inn:ban]
1h-pyrazole-3-aceticacid, 4-(4-chlorophenyl)-1-(4-fluorophenyl)-
SCHEMBL153631
pirazolac [mi]
pirazolac [mart.]
pirazolac [usan]
pirazolac [inn]
DTXSID00221233
[1-(4-fluorophenyl)-4-(4-chlorophenyl)-1h-pyrazol-3-yl]-acetic acid
YAMFWQIVVMITPG-UHFFFAOYSA-N
CS-0018134
HY-100146
Q27278246
AKOS040734901

Research Excerpts

Overview

Pirazolac (PAA) is a new non-steroidal anti-inflammatory drug (NSAID) belonging to the subgroup of heterocyclic acetic acids.

ExcerptReferenceRelevance
"Pirazolac (PAA) is a new non-steroidal anti-inflammatory drug (NSAID) belonging to the subgroup of heterocyclic acetic acids. "( The pharmacokinetics of pirazolac in human subjects.
Täuber, U, 1990
)
2.03

Toxicity

ExcerptReferenceRelevance
" In the pirazolac group 15% of the patients and in the sulindac group 11% dropped out from the study due to adverse clinical experience."( Multicentre double-blind study of the efficacy, safety and tolerance of pirazolac compared with sulindac in patients with rheumatoid arthritis.
Numo, R, 1990
)
0.95

Pharmacokinetics

ExcerptReferenceRelevance
" It has an intermediate elimination half-life of 17 h which does not depend on age or sex."( The pharmacokinetics of pirazolac in human subjects.
Täuber, U, 1990
)
0.59

Bioavailability

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34

Dosage Studied

Twenty-four patients with classical or definite rheumatoid arthritis participated in a 4-week double-blind crossover study to compare the effectiveness of two different dosage regimens. The average pirazolac concentration in plasma within the dosing interval fluctuated between 30 and 40 mg.

ExcerptRelevanceReference
" Plasma levels of PAA were monitored every day just before dosing and up to 72 hours after the last dose using a specific HPLC-method."( Pharmacokinetics of pirazolac, a new anti-inflammatory drug, in human volunteers. III. Steady state plasma levels.
Beiersdorff, RO; Matthes, H; Täuber, U,
)
0.45
" The average pirazolac concentration in plasma within the dosing interval fluctuated between 30."( Transsynovial distribution and protein binding of pirazolac in patients with rheumatoid arthritis.
Dunky, A; Geddawi, M; Kurowski, M, 1986
)
0.89
"Twenty-four patients with classical or definite rheumatoid arthritis participated in a 4-week double-blind crossover study to compare the effectiveness of two different dosage regimens of pirazolac."( Differential dosing study of pirazolac, a new non-steroidal anti-inflammatory agent, in patients with rheumatoid arthritis.
Clark, B; Geddawi, M; Panayi, G; Symmons, D, 1985
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (40.00)18.7374
1990's5 (50.00)18.2507
2000's1 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]